News

The Latvian Medicines Verification System (LZVS) will be updated to release 4.0 on May 21 this year. The installation of the release is scheduled for overnight starting at 21:00, during which temporary interruptions in system operation are possible.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.21)”.

In the event of a recall of a batch, withdrawal of a product from the market or a case of stolen packages, the marketing authorisation holder (MAH) should perform appropriate decommissioning transactions in the EMVS system for the affected markets, reminds the Latvian Medicines Verification Organization (LZVO).

The European Medicines Verification Organisation (EMVO) has launched the EMVS Community Newsletter - edition April 2024. This month, newsletter focusing on Data Quality, featuring insights from EMVO, the Dutch NMVO, Accord Healthcare, and end-user perspectives from the healthcare sector.

LZVO releases newsletter No. 9, where you can find the most important information about events in verification system and our neighbors in Lithuania sharing their experience story.

The performance and operation of the Latvian Medicines Verification System (LZVS) in the first quarter of 2024 have been stable. In the first quarter of 2024, a total of 29 million transactions were carried out in the LZVS, which is a 6% increase compared to the corresponding period in 2023.